Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced mouse model of Parkinson's disease

Journal of Neurochemistry

Volumn 91, Issue 2, 2004, Pages 285-298

  Vaglini, Francesca ^a   Pardini, Carla ^a   Viaggi, Cristina ^a   Bartoli, Cristina ^a   Dinucci, Dinuccio ^a   Corsini, Giovanni Umberto ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Cytochrome P450 2E1; Diethyldithiocarbamate; Neurodegeneration; Neurotoxicity; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; ALLYL SULFIDE; CYTOCHROME P450 2E1; DIETHYLTHIOCARBAMATE; DOPAMINE; HOMOVANILLIC ACID; ISOTHIOCYANIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DETOXIFICATION; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MALE; METABOLITE; MICRODIALYSIS; MOUSE; NERVE CELL DEGENERATION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WESTERN BLOTTING; WILD TYPE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ALLYL COMPOUNDS; ANIMALS; BLOTTING, WESTERN; CYTOCHROME P-450 CYP2E1; DISEASE MODELS, ANIMAL; DITIOCARB; DOPAMINE; DRUG SYNERGISM; ENZYME INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRODIALYSIS; NEOSTRIATUM; PARKINSONIAN DISORDERS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; SULFIDES; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; MUS MUSCULUS;

EID: 5444243967     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02720.x     Document Type: Article

References (83)

1. Anandatheerthavarada H. K., Williams J. F. and Wecker L. (1993) Differential effect of chronic nicotine administration on brain cytochrome P4501A1/2 and P4502E1. Biochem. Biophys. Res. Commun. 194, 312-318.
2. Bachurin S. O., Shevtzova E. P., Lermontova N. N., Serkova T. P. and Ramsay R. R. (1996) The effect of dithiocarbamates on neurotoxic action of 1-methy 1-4-pheny 1-1,2,3,6 tetrahydropyridine (MPTP) and on mitochondrial respiration chain. Neurotoxicology 17, 897-904.
3. Barlow B. K., Thiruchelvam M. J., Bennice L., Cory-Slechta D. A., Ballatori N. and Richfield E. K. (2003) Increased synaptosomal dopamine content and brain concentration of paraquat produced by selective dithiocarbamates. J. Neurochem. 85, 1075-1086.
4. Bhamre S., Anandatheerthavarada H. K., Shankar S. K. and Ravindranath V. (1992) Microsomal cytochrome P450 in human brain regions. Biochem. Pharmacol. 44, 1223-1225.
5. Brady J. F., Ishizaki H., Fukuto J. M., Lin M. C., Fadel A., Gapac J. M. and Yang C. S. (1991) Inhibition of cytochrome P-450 2E1 by diallyl sulfide and its metabolites. Chem. Res. Toxicol. 4, 642-647.
6. Cashman J. R. and Ziegler D. M. (1985) Contribution of N-oxygenation to the metabolism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) by various liver preparations. Mol. Pharmacol. 29, 163-167.
7. Cassee F. R., Groton J. P., Van Bladeren P. J. and Feron V. J. (1998) Toxicology of chemical mixtures: international perspective. Crit. Rev. Toxicol. 28, 73-101.
8. Chang T. K. H., Gonzalez F. J. and Waxman D. J. (1994) Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys. 311, 437-442.
9. Chiba K., Trevor A. and Castagnoli N. Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120, 1228-1232.
10. Coleman T., Ellis S. W., Martin I. J., Lennard M. S. and Tucker G. T. (1996) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4 - implications for susceptibility to Parkinson's disease. J. Pharmacol. Exp. Ther: 277, 685-690.
11. Colzi A., d'Agostini F., Kettler R., Borroni E. and Da Prada M. (1990) Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study. J. Neural Transm. Suppl. 32, 79-84.
12. Corsini G. U., Pintus S., Chiueh C. C., Weiss J. F. and Kopin I. J. (1985) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate. Eur. J. Pharmacol. 119, 127-128.
13. Corsini G. U., Zuddas A., Bonuccelli U., Schinelli S. and Kopin I. J. (1987) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by ethanol or acetaldehyde. Life Sci. 40, 827-832.
14. Corsini G. U., Maggio R. and Vaglini F. (2002) Molecular and cellular events regulating dopamine neuron survival, in Handbook of Experimental Pharmacology, Vol. 154 Part II: Dopamine in the CNS (Di Chiara G., ed.), pp. 321-386. Springer, Berlin.
15. Cotè S. L., Ribeiro-da-Silva A. and Cuello A. C. (1993) Current protocols for light microscopy immunocytochemistry, in Immunohistochemistry II (Cuello, A. C., ed.), pp. 147-168. John Wiley, Chichester.
16. Davis C. G., Williams A. C., Markey S. P., Ebert M. H., Calne E. D., Reichert C. M. and Kopin I. J. (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1, 249-254.
17. Denton T. and Howard B. D. (1987) A dopaminergic cell line variant resistant to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurochem. 49, 622-629.
18. Di Monte D., Jewell S. A., Ekstromm G., Sandy M. S. and Smith M. T. (1986) 1-Methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes. Biochem. Biophys. Res. Commun. 137, 310-315.
19. Doolen S. and Zahniser N. R. (2001) Protein tyrosine kinase inhibitors alter human dopamine transporter activity in xenopus oocytes. J. Pharmacol. Exp. Ther. 296, 931-938.
20. Fang J. (2000) Metabolism of clozapine by rat brain: the role of flavin-containing monooxygenase (FMO) and cytochrome P450 enzymes. Eur. J. Drug. Metab. Pharmacokinet. 25, 109-114.
21. Farin F. M. and Omiecinski C. J. (1993) Regiospecific expression of cytochrome P-450s and microsomal epoxide hydrolase in human brain tissue. J. Toxicol. Environ. Health 40, 317-335.
22. 3H]dopa in various regions of the brain. J. Neurochem. 13, 655-669.
23. Guengerich F. P., Kim D. and Iwasaki M. (1991) Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4, 168-179.
24. Guo Z., Smith T. J., Wang E., Sadrieh N., Ma Q., Thomas P. E. and Yang C. S. (1992) Effects of phenylethylisotiocyanate, a carcinogenesis inhibitor, on xenobiotic-metabolizing enzymes and nitrosamine metabolism in rats. Carcinogenesis 13, 2205-2210.
25. Haglund L., Kohler C., Haaparanta T., Goldstein M. and Gustafsson J. A. (1984) Presence of NADPH-cytochrome P450 reductase in central catecholaminergic neurones. Nature 307, 259-262.
26. Hansson T., Tindberg N., Ingelman-Sundberg M. and Kohler C. (1990) Regional distribution of ethanol-inducible cytochrome P450 IIE1 in the rat central nervous system. Neuroscience 34, 451-463.
27. Hedlund E., Wyss A., Kainu T., Backlund M., Kohler C., Pelto-Huikko M., Gustafsson J. A. and Warner M. (1996) Cytochrome P450 2D4 in the brain: specific neuronal regulation by clozapine and toluene. Mol. Pharmacol. 50, 342-350.
28. Hedlund E., Gustafsson J. A. and Warner M. (2001) Cytochrome P450 in the brain; a review. Curr. Drug. Metab. 2, 245-263.
29. Irwin I., Langston J. W. and DeLanney L. E. (1987a) 4-Phenylpyridine (4PP) and MPTP: the relationship between striatal MPP+ concentrations and neurotoxicity. Life Sci. 40, 726-731.
30. Irwin I., Wu E. Y., DeLanney L. E., Trevor L. and Langston J. W. (1987b) The effect of diethyldithiocarbamate on the biodisposition of MPTP: an explanation for enhanced neurotoxicity. Eur. J. Pharmacol. 141, 209-217.
31. + by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur. J. Pharmacol. 106, 455-156.
32. Javitch J. A., D'Amato R. J., Strittmatter S. M. and Snyder S. H. (1985) Parkinsonism-inducing neurotoxin, N-methy 1-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite W-methyl-4-phenyl-pyridine by dopamine neurons explains selective toxicity. Proc. Natl Acad. Sci. USA 82, 2173-2177.
33. Kim R. B. (2002) Pharmacogenetics of CYP enzymes and drug transporters: remarkable recent advances. Adv. Drug. Deliv. Rev. 54, 1241-1242.
34. Kohler C., Eriksson L. G., Hansson T., Warner M. and Ake-Gustafsson J. (1988) Immunohistochemical localization of cytochrome P-450 in the rat brain. Neurosci. Lett. 84, 109-114.
35. Kopin I. J. (1992) Mechanisms of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine induced destruction of dopaminergic neurons, in Handbook of Experimental Pharmacology, Vol. 102: Selective neurotoxicity (Herken H. and Hucho F., eds), pp. 333-356. Springer, Berlin.
36. Langston J. W., Ballard P., Tetrud J. W. and Irwin I. (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980.
37. Lau Y. S., Trobough K. L., Crampton J. M. and Wilson J. A. (1990) Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine (MPTP)-treated mice. Gen. Pharmacol. 21, 181-187.
38. Le Couleur D. G. and McCann S. J. (1998) P450 enzymes and Parkinson's disease. Mov. Disord. 13, 851-852.
39. Lee S. S., Buters J. T., Pineau T., Fernandez-Salguero P. and Gonzalez F. J. (1996) Role of CYP2E1 in the hepatotoxicity of acetaminophen. J. Biol. Chem. 271, 12063-12067.
40. Liang Z., Engrav L. H., Muangman P., Muffley L. A., Zhu K. Q., Carrougher G. J., Underwood R. A. and Gibran N. S. (2004) Nerve quantification in female red Duroc pig (FRDP) scar compared to human hypertrophic scar. Burns 30, 57-64.
41. Lieber C. S. (1990) Mechanism of ethanol induced hepatic injury. Pharmacol. Ther. 46, 1-41.
42. Lieber C. S. (1997) Cytochrome P450 2E1: its physiological and pathological role. Physiol. Rev. 77, 517-544.
43. Lowry O. H., Rosenbrough N. J., Farr A. L. and Randall R. J. (1951) Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265-275.
44. Markey S. P., Johannessen J. N., Chiueh C. C., Bums R. S. and Herkenham M. A. (1984) Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311, 464-167.
45. McGrew D. M., Irwin I. and Langston J. W. (2000) Ethylene- bisdithiocarbamate enhances MPTP-induced striatal dopamine depletion in mice. Neurotoxicology 21, 309-312.
46. +. J. Neurochem. 57, 541-549.
47. Mohanakumar K. P., Thomas B., Sharma S. M., Muralikrishnan D., Chowdhury R. and Chiueh C. C. (2002) Nitric oxide: an antioxidant and neuroprotector. Ann. N. Y. Acad. Sci. 962, 389-401.
48. Narimatsu S., Tachibana M., Masubuchi Y. and Suzuki T. (1996) Cytochrome P450, 2D and -2C enzymes catalyze the oxidative N-demethylation of the parkinsonism-inducing substance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rat liver microsomes. Chem. Res. Toxicol. 9, 93-98.
49. Newton D. J., Wang R. W. and Lu A. Y. H. (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug. Metab. Dispos. 23, 154-158.
50. Nicklas W. J., Vyas I. and Heikkila R. E. (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36, 2503-2508.
51. Nissbrandt H., Bergquist F. and Jonason J. (2001) Inhibition of cytochrome P450 2E1 induces an increase in extracellular dopamine in rat substantia nigra: a new metabolic pathway? Synapse 40, 294-301.
52. 1H]GBR-12935 binding proteins. Arch. Biochem. Biophys. 276, 424-432.
53. Norris P. J., Hardwick J. P. and Emson P. C. (1996) Regional distribution of Cytochrome P450 2D1 in the rat central nervous system. J. Comp. Neurol. 366, 244-258.
54. Parkinson A. (1996) Biotransformation of xenobiotics, in Casarett and Doull's Toxicology. The Basic Science of Poison (5th edn). (Klaassen C.D. ed.), pp. 113-186. McGraw-Hill, New York.
55. Paxinos G. and Franklin K. B. J. (2001) The Mouse Brain in Stereotaxic Coordinates (2nd edn). Academic Press, Hong Kong.
56. Perry T. L., Yong V. W., Jones K., Wall R. A., Clavier R. M., Foulks J. G. and Wright J. M. (1985) Effects of N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine and its metabolite, N-methyl-4-phenylpyridinium ion, on dopaminergic nigrostriatal neurons in the mouse. Neurosci. Lett. 58, 321-326.
57. Petroske R. R., Meredith G. E., Callen S., Totterdell S. and Lau Y. S. (2001) Mouse model of parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 106, 589-601.
58. Ramsay R. R. and Singer T. P. (1986) Energy-dependent uptake of 1-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261, 7885-7887.
59. Ravindranath V., Anandatheerthavarada H. K. and Shankar S. K. (1989) Xenobiotic metabolism in human brain - presence of cytochrome P-450 and associated mono-oxygenases. Brain Res. 496, 331-335.
60. Riedl A. G., Watts P. M., Edwards R. J., Schulz-Utermoehl T., Boobis A. R., Jenner P. and Marsden C. D. (1999) Expression and localisation of CYP2D enzymes in rat basal ganglia. Brain Res. 822, 175-191.
61. Schlinger B. A. and Callard G. V. (1989) Localization of aromatase in synaptosomal and microsomal subfractions of quail (Coturnix coturnix japonica) brain. Neuroendocrinology 49, 434-441.
62. Shang T., Uihlein A. V., Van Asten J., Kalyanaraman B. and Hillard C. J. (2003) 1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter. J. Neurochem. 85, 358-367.
63. Sohda T., Shimizu M., Kamimura S. and Okumura M. (1993) Immunohistochemical demonstration of ethanol-inducible P450 2E1 in rat brain. Alcohol Alcohol. Suppl. 28, 69-75.
64. Sonsalla P. K. and Nicklas W. J. (1992) MPTP and animal models of Parkinson's disease, in Handbook of Parkinson's Disease (2nd edn) (Koller W. C., ed), pp. 319-340. Marcel Dekker, New York.
65. Stott I., Murthy A., Robinson A., Thomas N. W. and Fry J. R. (1997) Low-dose diethyldithiocarbamate attenuates the hepatotoxicity of 1,3-dichloro-2-propanol and selectively inhibits CYP 2E1 activity in the rat. Hum. Exp. Toxicol. 16, 262-266.
66. Takahashi R. N., Rogerio R. and Zanin M. (1989) Maneb enhances MPTP neurotoxicity in mice. Res. Commun. Chem. Pathol. Pharmacol. 66, 167-170.
67. Taylor E. M. (2002) The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin. Pharmacokinet. 41, 81-92.
68. Teel R. W. and Huynh H. (1998) Modulation by phytochemicals of cytochrome P450-linked enzyme activity. Cancer Lett. 133, 135-141.
69. Teismann P., Tieu K., Cohen O., Choi D. K., Wu D. C., Marks D., Vila M., Jackson-Lewis V. and Przedborski S. (2003) Pathogenic role of glial cells in Parkinson's disease. Mov. Disord. 18, 121-129.
70. Tindberg N. and Ingelman-Sundberg M. (1996) Expression, catalytic activity, and inducibility of cytochrome P450 2E1 (CYP 2E1) in the rat central nervous system. J. Neurochem. 67, 2066-2073.
71. Vaccari A., Saba P. L., Ruiu S., Collu M. and Devoto P. (1996) Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine. Toxicol. Appl. Pharmacol. 139, 102-108.
72. + levels do not necessarily correlate with striatal dopamine levels after MPTP treatment in mice. Neurodegeneration 5, 129-136.
73. Walters T. L., Irwin I., Delfini K., Langston J. W. and Janson A. M. (1999) Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP. Exp. Neurol. 156, 62-70.
74. Warner M., Wyss A., Yoshida S. and Gustafsson J. A. (1994) Cytochrome P450 enzymes in brain, in Methods in Neurosciences, Vol. XXII, pp. 51-66. Academic Press, New York.
75. Watts P. M., Riedl A. G., Douek D. C., Edwards R. J., Boobis A. R., Jenner P. and Marsden C. D. (1998) Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase. Neuroscience 86, 511-519.
76. Weissman J., Trevor A., Chiba K., Peterson L. A., Caldera P., Castagnoli N. Jr and Baillie T. (1985) Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by liver homogenate 1,2,3,6-tetrahydropyridine by liver homogenate fractions. J. Med. Chem. 28, 997-1001.
77. Wu R. M., Cheng C. W., Chen K. H., Shan D. E., Kuo J. W., Ho Y. F. and Chern H. D. (2002) Genetic polymorphism of the CYP 2E1 gene and susceptibility to Parkinson's disease in Taiwanese. J. Neural Transm. 109, 1403-1414.
78. 2) and evidence for the expression of the transporter in the brain. J. Biol. Chem. 49, 32776-32786.
79. Yurek D. M., Deutch A. Y., Roth R. H. and Sladek J. R. (1989) Morphological, neurochemical, and behavioral characterizations associated with the combined treatment of diethyldithiocarbamate and 1-methy 1-4-pheny 1-1,2,3,6-tetrahydropyridine in mice. Brain Res. 497, 250-259.
80. Zhang L., Dresser M. J., Gray A. T., Yost S. C., Terashita S. and Giacomini K. M. (1997) Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. 51, 913-921.
81. Zuddas A., Corsini G. U., Schinelli S., Barker J. L., Kopin I. J. and di Porzio U. (1989a) Acetaldehyde directly enhances MPP+ neurotoxicity and delays its elimination from the striatum. Brain Res. 501, 11-22.
82. Zuddas A., Corsini G. U., Schinelli S., Johannessen J. N., Di Porzio U. and Kopin I. J. (1989b) MPTP treatment combined with ethanol or acetaldehyde selectively destroys dopaminergic neurons in mouse substantia nigra. Brain Res. 501, 1-10.
83. Zuddas A., Oberto G., Vaglini F., Fascetti F., Fornai F. and Corsini G. U. (1992) MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in primates. J. Neurochem. 59, 733-739.